Published in Blood on June 30, 2009
TAM receptor signaling and autoimmune disease. Curr Opin Immunol (2010) 1.63
Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Invest (2009) 1.47
Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation. Blood (2015) 1.41
Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood (2010) 1.30
The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood (2009) 1.21
TAM receptor signaling in immune homeostasis. Annu Rev Immunol (2015) 1.18
T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity (2013) 1.14
Vitamin K and the nervous system: an overview of its actions. Adv Nutr (2012) 1.03
Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function. Blood (2014) 1.02
Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. J Neurosci (2010) 0.93
Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Mol Neurodegener (2011) 0.88
Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm Bowel Dis (2014) 0.84
Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol (2013) 0.84
Dendritic cells in systemic lupus erythematosus. Int Rev Immunol (2010) 0.83
ELISA-Based Detection System for Protein S K196E Mutation, a Genetic Risk Factor for Venous Thromboembolism. PLoS One (2015) 0.82
Systemic autoimmunity in TAM triple knockout mice causes inflammatory brain damage and cell death. PLoS One (2013) 0.82
Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain. Blood (2010) 0.81
Regulation of phagocytosis by TAM receptors and their ligands. Front Biol (Beijing) (2010) 0.80
Platelet protein S directly inhibits procoagulant activity on platelets and microparticles. Thromb Haemost (2012) 0.79
Phosphorylation of protein S by platelet kinases enhances its activated protein C cofactor activity. FASEB J (2013) 0.79
TAM receptor tyrosine kinase function and the immunopathology of liver disease. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation. Thromb Haemost (2013) 0.75
A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics (2001) 15.03
A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res (2003) 12.94
c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature (2001) 4.46
Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science (2001) 4.42
Immunobiology of the TAM receptors. Nat Rev Immunol (2008) 4.26
The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell (1995) 4.13
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66
Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A (2006) 2.01
TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci (2006) 1.96
Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood (1997) 1.94
Protection against thrombosis in mice lacking PAR3. Blood (2002) 1.74
Nestin-Cre transgenic mouse line Nes-Cre1 mediates highly efficient Cre/loxP mediated recombination in the nervous system, kidney, and somite-derived tissues. Genesis (2006) 1.74
Zfp423 is required for normal cerebellar development. Mol Cell Biol (2006) 1.62
Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood (2000) 1.58
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest (1998) 1.55
Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem (1993) 1.51
Homozygous protein S deficiency: 7-year follow-up. Thromb Haemost (1996) 1.49
Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem (2002) 1.45
Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem (1986) 1.45
Genetic risk factors of venous thrombosis. Hum Genet (2001) 1.40
Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A (1994) 1.25
Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for Mer tyrosine kinase-mediated phagocytosis of apoptotic cells. J Immunol (2008) 1.18
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation (2001) 1.17
Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. J Clin Invest (2005) 1.17
Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem (1995) 1.17
Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis (2003) 1.15
Molecular basis of protein S deficiency. Thromb Haemost (2007) 1.14
Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost (2008) 1.08
Regulation of coagulation by protein S. Curr Opin Hematol (2008) 1.03
Development of a calibrated automated thrombography based thrombin generation test in mouse plasma. J Thromb Haemost (2007) 0.97
Direct anticoagulant activity of protein S-C4b binding protein complex in Heerlen heterozygotes and normals. J Thromb Haemost (2004) 0.97
Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. Blood (2007) 0.97
A guide to murine coagulation factor structure, function, assays, and genetic alterations. J Thromb Haemost (2007) 0.97
A novel ELISA for mouse activated protein C in plasma. J Immunol Methods (2006) 0.97
Protein S deficiency: a database of mutations--summary of the first update. Thromb Haemost (2000) 0.92
The gene coding for the beta-chain of C4b-binding protein (C4BPB) has become a pseudogene in the mouse. Genomics (1994) 0.89
Tissue-specific transgenic and knockout mice. Methods Mol Biol (2006) 0.87
The absence of the blood clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Thromb Haemost (1995) 0.86
Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene. Thromb Haemost (1994) 0.85
Differential expression of tissue factor mRNA and protein expression in murine sepsis. The role of the granulocyte revisited. Thromb Haemost (2006) 0.82
Protein S deficiency. Haematologica (2008) 0.81
Protein S is a cofactor for tissue factor pathway inhibitor. Thromb Res (2008) 0.80
Late onset thrombosis in a case of severe protein S deficiency due to compound heterozygosity for PROS1 mutations. J Thromb Haemost (2008) 0.79
The cytoprotective protein C pathway. Blood (2006) 5.75
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med (2003) 4.04
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med (2007) 3.35
Nucleophilic catalysis of oxime ligation. Angew Chem Int Ed Engl (2006) 2.69
Endothelial and antithrombotic actions of HDL. Circ Res (2006) 2.68
Nucleophilic catalysis of hydrazone formation and transimination: implications for dynamic covalent chemistry. J Am Chem Soc (2006) 2.45
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med (2004) 2.45
Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron (2004) 2.23
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med (2006) 2.22
Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med (2009) 2.15
Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost (2009) 2.05
Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J (2003) 1.91
Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest (2009) 1.86
Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med (2011) 1.84
Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet (2003) 1.72
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood (2004) 1.68
Local regulation of fat metabolism in peripheral nerves. Genes Dev (2003) 1.67
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem (2007) 1.67
Phosphatidic acid mediates demyelination in Lpin1 mutant mice. Genes Dev (2008) 1.61
Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood (2004) 1.61
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem (2006) 1.58
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med (2012) 1.58
Ion exchangers NHX1 and NHX2 mediate active potassium uptake into vacuoles to regulate cell turgor and stomatal function in Arabidopsis. Plant Cell (2012) 1.54
Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53
Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 1.50
Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb Haemost (2008) 1.49
Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A (2008) 1.45
Effect of hyperhomocysteinemia on protein C activation and activity. Blood (2002) 1.45
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest (2010) 1.41
Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies. J Clin Invest (2016) 1.41
SH3TC2/KIAA1985 protein is required for proper myelination and the integrity of the node of Ranvier in the peripheral nervous system. Proc Natl Acad Sci U S A (2009) 1.39
Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol (2002) 1.38
Impact of Hospital Admission Care At a Pediatric Unit: A Qualitative Study. Pediatr Nurs (2016) 1.38
In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat Med (2011) 1.38
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood (2009) 1.36
Retracted Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood (2009) 1.36
Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood (2012) 1.35
The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res (2008) 1.34
Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci (2008) 1.33
High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation (2005) 1.31
Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem (2002) 1.30
Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci (2009) 1.30
Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol (2005) 1.26
Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation. Transfusion (2012) 1.22
The AtNHX1 exchanger mediates potassium compartmentation in vacuoles of transgenic tomato. Plant J (2009) 1.21
Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. Am J Respir Crit Care Med (2012) 1.18
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke (2012) 1.18
Endothelial junctional adhesion molecule-a guides monocytes into flow-dependent predilection sites of atherosclerosis. Circulation (2013) 1.18
Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood (2009) 1.17
Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood (2011) 1.17
High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation (2007) 1.16
Role of Gas6 in erythropoiesis and anemia in mice. J Clin Invest (2008) 1.16
Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis (2003) 1.15
Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A (2014) 1.14
Early atherosclerosis exhibits an enhanced procoagulant state. Circulation (2010) 1.14
Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovasc Imaging (2009) 1.12
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood (2007) 1.12
Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes (2004) 1.11
Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb Haemost (2009) 1.10
Lipid raft adhesion receptors and Syk regulate selectin-dependent rolling under flow conditions. Blood (2006) 1.07
Binding of S-methyl-5'-thioadenosine and S-adenosyl-L-methionine to protein MJ0100 triggers an open-to-closed conformational change in its CBS motif pair. J Mol Biol (2009) 1.07
SH3TC2, a protein mutant in Charcot-Marie-Tooth neuropathy, links peripheral nerve myelination to endosomal recycling. Brain (2010) 1.06
Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots. Cancer Res (2008) 1.06
Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Sci (2002) 1.06
SCAP is required for timely and proper myelin membrane synthesis. Proc Natl Acad Sci U S A (2009) 1.05
A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Hum Mol Genet (2013) 1.05
Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation (2011) 1.05
Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: role of human fucosyltransferase-IV and -VII. J Biol Chem (2004) 1.05
Design and synthesis of a bimodal target-specific contrast agent for angiogenesis. Org Lett (2004) 1.04
Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr Pharm Des (2013) 1.03
Regulation of coagulation by protein S. Curr Opin Hematol (2008) 1.03
Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice. Am J Respir Cell Mol Biol (2011) 1.02
Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med (2014) 1.02
The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa. Thromb Haemost (2012) 1.01
Molecular magnetic resonance imaging of myocardial angiogenesis after acute myocardial infarction. Circulation (2010) 1.00
An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. J Neurosci (2013) 1.00
Identification of distinct sequences in human blood coagulation factor Xa and prothrombin essential for substrate and cofactor recognition in the prothrombinase complex. J Biol Chem (2003) 0.99
Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J Neurochem (2009) 0.99
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res (2007) 0.98
Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev (2012) 0.98
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des (2012) 0.98